Share on StockTwits

Luminex (NASDAQ:LMNX)‘s stock had its “underweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday. They currently have a $17.00 price objective on the stock, down from their previous price objective of $18.00. JPMorgan Chase & Co.’s price target would suggest a potential downside of 10.53% from the stock’s previous close.

Shares of Luminex (NASDAQ:LMNX) traded up 8.14% on Tuesday, hitting $19.00. The stock had a trading volume of 649,310 shares. Luminex has a one year low of $15.74 and a one year high of $22.30. The stock has a 50-day moving average of $17.34 and a 200-day moving average of $18.00. The company has a market cap of $807.9 million and a price-to-earnings ratio of 48.01.

Luminex (NASDAQ:LMNX) last released its earnings data on Monday, July 28th. The company reported $0.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.10. The company had revenue of $55.50 million for the quarter, compared to the consensus estimate of $55.90 million. During the same quarter last year, the company posted $0.09 earnings per share. Luminex’s revenue was up 2.4% compared to the same quarter last year. Analysts expect that Luminex will post $0.50 EPS for the current fiscal year.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Luminex in a research note on Wednesday, April 30th. They now have a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $19.50.

Luminex Corporation (NASDAQ:LMNX)develops, manufactures and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.